OncBioMune Research Shows Activity of PGT Technology in a Mammary Cancer Animal Model

OncBioMune Pharmaceuticals (OTCMKTS:OBMP) announced results of pre-clinical research that support further development of the Company’s patented, novel paclitaxel gallium transferrin (PGT) technology for the treatment of multiple types of cancer.
As quoted in the press release:

OncBioMune first tested PGT against a series of human cell lines to evaluate activity in models of breast, colon, lung and three human cell lines of ovarian cancer, including a drug-resistant ovarian cancer model. The results showed PGT to act as an inhibitor of all tumor cell lines, including the drug-resistant ovarian cancer model.
OncBioMune then conducted research to develop an animal model to evaluate the activity of PGT and selected the 4T1 murine mammary carcinoma tumor model. The 4T1 murine mammary carcinoma is recognized as one of the most aggressive cancer cell lines and is known to rapidly metastasize to sites similar to human breast cancer. OncBioMune developed its own 4T1 mouse model and showed an intraperitoneal injection of PGT worked as an inhibitor of 4T1 mammary tumors. Importantly, no gross organ toxicities at necropsy were observed.

OncBioMune Pharmaceuticals CEO, Dr. Jonathan Head, stated:

These early studies demonstrated that our PGT technology has a wide spectrum of activity against several difficult to treat cancers. The data warrants additional research as we continue to widen our pipeline with cancer drug candidates. We are pleased with all the data and particularly impressed with the results in the drug-resistant ovarian cancer cell line. We believe there are several opportunities to explore FDA pathways to expedite development for this indication.

Connect with OncBioMune Pharmaceuticals (OTCMKTS:OBMP) to receive an Investor Presentation.